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Although Ras and Rap1 share interaction with com-
mon candidate effector proteins, Rap1 lacks the trans-
forming activity exhibited by Ras proteins. It has been
speculated that Rap antagonizes Ras transformation
through the formation of nonproductive complexes with
critical Ras effector targets. To understand further the
distinct biological functions of these two closely related
proteins, we searched for Rap1b-binding proteins by
yeast two-hybrid screening. We identified multiple
clones that encode the COOH-terminal sequences of a
protein that shares sequence identity with RalGDS and
RGL, which we have designated RGL2. A 158-amino acid
COOH-terminal fragment of RGL2 (RGL2 C-158) bound
to Ras superfamily proteins which shared identical ef-
fector domain sequences with Rap1 (Ha-Ras, R-Ras, and
TC21). RGL2 C-158 binding was impaired by effector
domain mutations in Rap1b and Ha-Ras. Furthermore,
RGL2 C-158 bound exclusively to the GTP-, but not the
GDP-bound form of Ha-Ras. Finally, coexpression of
RGL2 C-158 impaired oncogenic Ras activation of tran-
scription from a Ras-responsive promoter element and
focus-forming activity in NIH 3T3 cells. We conclude
that RGL2 may be an effector for Ras and/or Rap
proteins.
Ras function is crucial for cell growth and differentiation (1).
Ras, as a signaling molecule, is an allosteric switch that cycles
between an active GTP-bound conformation and an inactive
GDP-bound form. The nucleotide bound state of Ras is regu-
lated by Ras guanine nucleotide exchange factors (GEFs;1 SOS
and RasGRF), which activate Ras by promoting an exchange of
GDP for GTP. Conversely, Ras GTPase-activating proteins
(GAPs; p120- and nuclear factor-1 GAP) inactivate Ras by
stimulating the hydrolysis of GTP to GDP (2). Activating mu-
tations of Ras (positions 12, 13, and 61) render Ras insensitive
to GAP-stimulated GTPase activity (3). Ras interacts with and
participates in Raf-1 activation. Activation of Raf-1 kinase ac-
tivity results in the phosphorylation of the mitogen-activated
protein kinase (MAPK) kinase MEK, which in turn phospho-
rylates the p42 and p44 MAPKs ERK-1 and ERK-2 (4). Acti-
vatedMAPKs translocate to the nucleus to regulate the activity
of Elk-1 and other nuclear targets. Active mutants of Ras cause
constitutive activation of the MAPK cascade and uncontrolled
cell growth.
Although Raf-1 has been demonstrated to be a critical down-
stream effector of Ras function, there is increasing evidence
that Ras may mediate its actions through activation of multiple
downstream effector-mediated pathways (5). First, there is an
increasing number of proteins that bind Ras and are candidate
Ras effectors, suggesting that Ras activates both Raf-depend-
ent and Raf-independent pathways. Like Raf-1, these function-
ally diverse proteins show preferential binding to the active
GTP-bound form of Ras, and this interaction requires an intact
Ras effector domain (amino acids 32–40). Included among
these are the two Ras GAPs, phosphatidylinositol-3-OH kinase,
GEFs for the Ral family of Ras-related proteins (RalGDS and
RGL), Rin-1, MEKK1, AF-6 and others (2, 6–13). Second, ob-
servations from genetic, biochemical, and biological studies
suggest that Ras triggers the activation of members of the Rho
family of Ras-related proteins and that Rho protein function is
necessary for full Ras transformation (14–17). At present, the
effector that connects Ras with Rho proteins is not known.
Third, the recent observation that Raf-binding defective mu-
tants of oncogenic Ras can still cause tumorigenic transforma-
tion supports the contribution of Raf-independent pathways to
Ras transforming activity (18). Taken together, these observa-
tions support the importance of establishing the role of non-Raf
effector targets in mediating Ras signaling and transformation.
Among Ras-related proteins, the closest relatives of Ras pro-
teins are R-Ras, TC21/R-Ras2, and Rap proteins (Rap1a and b
and Rap2a and b). Interestingly, Ras proteins, TC21, and R-
Ras have transforming capacity (19–22), whereas Rap proteins
do not (23). In fact, Rap1a (Krev-1) was originally isolated
based upon its ability to revert Ras-transformed NIH 3T3 cells
to a normal flat phenotype (24). In addition to sharing over 50%
sequence identity, Ras and Rap have identical sequences
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within their respective effector domains (amino acids 32–40)
(25, 26). A role for Rap1 as a Ras antagonist has been suggested
in several systems (27–32). The sequence identity shared be-
tween the effector domains of Ras and Rap1 taken together
with the ability of Rap1 to interact with Ras binding proteins,
such as Ras GAP (33, 34) and Raf-1 kinase (35), has led to the
speculation that Rap1 may antagonize Ras function through an
interaction, in a nonfunctional manner, with Ras effector mol-
ecules. Direct support for this model has not yet been
demonstrated.
As a step toward elucidating the functional basis for the
divergent biological activities of Ras and Rap proteins, we used
the yeast two-hybrid system to identify potential Rap1 effector
molecules (36, 37). We identified clones encoding a new mem-
ber of a growing family of candidate Ral GEFs which we have
termed RGL2. We observed that the COOH-terminal fragment
of RGL2 also bound to Ras and other Ras-related proteins
which share identical effector domain sequences (R-Ras and
TC21) and that binding to Rap and Ras was abolished by
mutations in their effector domains. Thus, like Raf, RGL2
exhibits properties as an effector for Ras and Rap function.
Finally, coexpression of the Ras-binding domain of RGL2
blocked oncogenic Ras signaling and transformation. We sug-
gest that RGL2 may represent an important effector for Ras
function and that Rap interaction with RGL2 may contribute to
Rap antagonism of Ras function.
EXPERIMENTAL PROCEDURES
Materials and Chemicals—pGBT9 (TRP1, ampr), containing the
GAL4 DNA binding domain, pGAD10 (LEU2, ampr), containing a hu-
man placental oligo(dT)-primed cDNA library fused to the GAL4 tran-
scriptional activation domain, and the Saccharomyces cerevisiae strain
HF7c were from Clontech (Palo Alto, CA). The vector pGBT9 carrying
cDNA sequences encoding wild type and T35A and G12V;C186G mu-
tant Ha-Ras proteins were provided by Linda van Aelst and Michael
Wigler (Cold Spring Harbor Laboratories, Cold Spring Harbor, NY).
[g-32P]GTP (30 Ci/mmol) and [a-32P]dCTP (3000 Ci/mmol) were from
ICN Pharmaceuticals Inc. (Costa Mesa, CA). [3H]GDP and [3H]GTP
(11.1 Ci/mmol) were from Amersham Crop. Sequenase was from U. S.
Biochemical Corp. AmpliTaq was from Perkin-Elmer. 5-Bromo-4-
chloro-3-indolyl b-D-galactoside was from Fisher.
Plasmid Constructions—Constructs encoding wild type Rap1b, Rheb,
Rac1, Rab3a, R-ras, and TC21 were made by PCR using primers that
created an EcoRI site at the 59 and a BamHI site at the 39 end of the
cDNA. cDNA sequences encoding G12V, G12V;C181G, S17N, E37G,
and T35A mutations were made by PCR and cloned using the same
restriction sites. The ralA cDNA was amplified and cloned as a BamHI
fragment. All of these fragments were cloned into the vector pGBT9.
The COOH-terminal 158 amino acids of RGL2 was used to generate a
GST fusion gene by digesting the vector pGAD10 carrying C-158 cDNA
with EcoRI. The cDNA insert was subsequently ligated into EcoRI-
digested pGEX-4T (Pharmacia Biotech Inc.). RGL2 RBD was con-
structed by PCR amplification of sequences encoding residues 1–98
(relative to C-158) with primers that created a 59 BamHI and 39 BglII
site. PCR products were digested with BamHI and BglII and cloned into
the BamHI site of the eukaryotic expression vector pCGN hygro (38).
All clones created by PCR were sequenced to ensure that undesired
mutations did not exist.
Two-hybrid Screening—The yeast strain HF7c carrying the Rap1b/
GAL4 DNA binding domain fusion was transformed with pGAD10
containing a human placenta cDNA library. Transformants capable of
forming large colonies after 4 days in the presence of 5 mM 3-aminotria-
zole were tested for b-galactosidase activity. The vector pGAD10 carry-
ing potential positive interacting cDNAs were rescued from yeast cells
and used to transform Escherichia coli strain HB101. Those cDNAs that
exhibited a Rap1-dependent b-galactosidase-positive genotype upon re-
transformation were characterized further.
cDNA Cloning and Sequencing—cDNA libraries (Stratagene, La-
Jolla, CA) from human placenta (Uni-ZAP XR), skeletal muscle (lZAP
II), heart (lZAP II), and testis (ZAP Express XR) were screened. In each
case 5.0 3 105 plaques were plated on E. coli strain XL-1 Blue MRF9.
The largest cDNA from the two-hybrid screening was used to make a
probe using the random priming procedure (Life Technologies, Inc.).
Plasmids were generated from positive plaques using the helper phage
Exassist (Stratagene). The 59-most 500 nucleotides of the largest cDNA
insert from the skeletal muscle library were used to rescreen each of the
l libraries. The largest clones were approximately 2 kilobases in length
and were sequenced using an ABI 373A automated sequenator (Applied
Biosystems). Specific oligonucleotide primers were purchased from
Oligo Therapeutics (Newtown, CT).
Two-hybrid Analysis of RGL2 C-158 Interaction with Small GTP-
binding Proteins—The yeast strain HF7c was cotransformed with
RGL2 C-158 and wild type or mutated small GTP-binding proteins.
Transformants were selected on minimal medium lacking tryptophan
and leucine. Colonies were then streaked on plates lacking tryptophan,
leucine, and histidine to assay for growth and b-galactosidase activity.
In Vitro Interaction of RGL2 C-158 with Rap1b and Ha-Ras—Rap1b
and Ha-Ras were loaded with GTP as follows. Approximately 10 nmol of
Rap1b in 32 mM Tris-HCl, pH 7.5, 200 mM NH4SO4, 0.5 mM EDTA, 10
mM dithiothreitol, 100–200 mM GTP, and 60 mCi [g-32P]GTP (30 Ci/
mmol) were incubated for 3 h at room temperature. MgCl2 was then
added to a final concentration of 5 mM. Similar amounts of Ha-Ras in 50
mM Tris-HCl, pH 7.5, 50 mM NaCl, 5 mM dithiothreitol, 100–200 mM
GTP, 60 mCi [g-32P]GTP (30 Ci/mmol), and 5 mM EDTA were incubated
for 5–10 min at room temperature. MgCl2 was then added to a final
concentration of 10 mM. Reactions were run on a Sephadex G-50 column
(equilibrated in 50 mM Tris-HCl, pH 7.5, 1 mg/ml polyethylene glycol
20,000, 10 mM MgCl2) to separate unbound GTP from GTP-bound Rap
or Ras. Typical loading efficiencies were 80% for Rap1 and 50% for
Ha-Ras.
For the binding studies 8 pmol of RGL2 C-158 GST fusion or GST
alone was bound to 50 ml of a 25% slurry of glutathione-Sepharose in
400 ml of binding buffer (1% Nonidet P-40, 20 mM Tris, pH 7.5, 150 mM
NaCl, 10 mM MgCl2, 1 mg/ml bovine serum albumin) at 4 °C for 20 min.
After several washes with binding buffer, Rap1b or Ha-Ras loaded with
[g-32P]GTP was added and incubated with agitation for 60 min at 4 °C.
Binding reactions were performed in a final volume of 250 ml. Reactions
were washed eight times with 400 ml of binding buffer, and the bound
nucleotide was quantified by liquid scintillation counting. For each
quantity of Rap1 or Ha-Ras used, specific binding was determined by
subtracting counts bound to GST alone from counts bound by RGL2
GST fusion protein.
In vitro interaction of RGL2 RBD with Ras-GDP and Ras-GTP was
determined by binding experiments as described above. RGL2 GST
fusion protein (8 pmol) or an equivalent amount of GST alone was
combined with various amounts of Ha-Ras loaded with either [3H]GDP
or [3H]GTP (11 Ci/mmol).
NIH 3T3 Transcription Activation and Transformation Assays—
NIH 3T3 cells were grown and transfected as described previously (39).
The (PyF)2-Luc reporter plasmid contains the luciferase (Luc) gene
driven by a minimal fos promoter containing two tandem copies of the
ets/AP-1 Ras-responsive promoter element from the polyomavirus en-
hancer (40). Cells were cotransfected with the pZIP-rasH(Q61L) plas-
mid DNA encoding Ha-Ras(Q61L) (100 ng/60-mm dish) and 5 mg of
either empty pCGN-hygro vector, pCGN-raf-N4 (encoding c-Raf-1 res-
idues 23–284) (38), or pCGN-RGL2 RBD along with 1 mg of the (PyF)2-
Luc reporter. Forty-eight h after transfection, total cell lysates were
prepared, and luciferase activity was determined as described (41). A
similar cotransfection was performed to assess the abilities of Raf-N4
and RGL2 RBD (5 mg/dish) to block Ras(Q61L) (10 ng/60-mm dish)
transforming/focus-forming activity. Transfections were performed in
duplicate, and transformed foci were quantitated after 14–16 days.
RESULTS
Identification of RalGDS-related Protein as a Rap1b-inter-
acting Protein—Although Ras and Rap share identical effector
domain sequences and interact with common candidate effector
proteins, they exhibit distinct signaling and biological activi-
ties. To understand further the relationship between Ras and
Rap1 signaling, we searched for Rap1b effectors using yeast
two-hybrid library screening. The yeast strain HF7c was co-
ransformed with a plasmid containing the GAL4 DNA binding
domain fused to Rap1b (pGBT9-Rap) and a plasmid containing
the GAL4 transcriptional activation domain fused to cDNAs
from a human placental cDNA library (pGAD10). From a total
of 4.8 3 106 transformants, we identified 238 His1 colonies.
Ninety-six of the 238 His1 colonies were positive for b-galacto-
sidase activity, and 48 possessed Rap1b-dependent b-galacto-
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sidase activity. We sequenced the 59 end of 23 of these clones
and found that they contained different size fragments of the
same gene. The smallest cDNA encoded the COOH-terminal
151 amino acids of the protein and defined this region as
sufficient for Rap1b-specific binding. The largest clone ob-
tained from the two hybrid screen was approximately 1.1 kilo-
bases in length. Although the largest clones obtained after
screening four libraries were approximately 2 kilobases in
length, Northern blot analysis indicated that the transcript is
approximately 3 kilobases in length (data not shown) indicat-
ing that these are not full-length clones. Further attempts to
obtain full-length cDNA have been unsuccessful. The sequence
of the partial cDNA was determined (Fig. 1A).
A comparison of the partial cDNA sequence with those in the
GenEMBL data base revealed a high degree of amino acid
sequence identity/similarity to RalGDS (42%/61%) and RGL
(40%/61%). Based on this similarity we have named this pro-
tein RGL2 (Ral GDS like 2). Like RalGDS and RGL, the NH2
terminus of RGL2 contains a sequence with significant simi-
larity to the catalytic domain of the yeast protein CDC25,
which functions as a Ras GEF (8–10, 42). Among the proteins
bearing CDC25 domains, the highest degree of similarity (62%)
exists with RalGDS and RGL, whereas RGL2 possessed only
50% similarity when compared with other CDC25-related do-
mains present in the mammalian Ras exchange factors Ras-
GRF, SOS1, or the Rap1 exchange factor C3G (43–45). High
levels of sequence identity were also seen in the COOH-termi-
nal portion of RGL2 when compared with RalGDS and RGL (49
and 47%, respectively) (Fig. 1B) (10). This sequence represents
the RBD of RalGDS and RGL. RGL2 did not show any obvious
sequence identity with any other known RBDs. Thus, like
RalGDS and RGL, RGL2 is composed of an NH2-terminal
CDC25 homology and a COOH-terminal RBD.
RGL2 Exhibits Properties of an Effector Target for Rap1 and
Ras—RalGDS shows preferential interaction with Ras-GTP
and requires an intact effector domain (8–10). Thus, RalGDS
exhibits properties of a candidate Ras effector target. To deter-
mine if RGL2 also possessed properties of an effector protein,
RGL2 C-158 was tested with various wild type and mutated
GTPases. Wild type and constitutively activated (G12V) mu-
tants of Rap1b and Ras interacted with very similar affinity in
the semiquantitative b-galactosidase filter assay (Table I). The
lack of an endogenous yeast GAP activity for Ras and Rap (46)
may explain why activating mutations do not result in higher
interaction with RGL2 C-158.
As shown in Table I, effector domain mutants Rap1b T35A
and Ras T35A were unable to interact with RGL2 C-158. These
results suggest that, like Raf-1, RGL2 binding requires an
intact effector domain. Interestingly, a second effector domain
mutation, Rap1b E37G, did interact with RGL2 C-158 with
nearly wild type affinities. Since the E37G mutation in Ras
inhibited its ability to interact with Raf, but not RalGDS, Raf-1
and RGL2 are predicted to have overlapping but distinct struc-
tural requirements for binding (18). Rap1b S17N, which by
analogy to the Ras S17N dominant negative mutant is thought
to have reduced affinity for GTP, showed no detectable inter-
action with RGL2 C-158, suggesting that RGL2 C-158 showed
preferential binding to the active GTP-bound form of Rap1b.
Mutant versions of Rap1b and Ras, with mutations in the
cysteine residues of their COOH-terminal CAAX prenylation
signal sequences (Rap1b G12V;C181G and Ras G12V;C186G)
retained strong binding. Thus, CAAX-dependent, post-transla-
tional modifications (e.g. prenylation) are not required for
RGL2 binding.
The fact that RGL2 interacted with both Ras and Rap1 and
that the interaction required the effector domain prompted us
to establish the specificity of the interaction between RGL2 and
other Ras-related GTPases. Although both Ras, Rap1, R-Ras,
and TC21/R-Ras2 share complete sequence identity within
their respective effector domains, R-Ras and TC21 interacted
with RGL2 C-158 to a lesser extent than did wild type and
activated forms of Ha-Ras and Rap1b. RGL2 C-158 displayed
some affinity for RalA and Rac1, although these two proteins
diverge significantly within their effector domain sequence
compared with Ras. Finally, we were unable to detect any
interaction of RGL2 C-158 with RhoA, Rab3a, or Rheb under
the same assay conditions (Table I). Thus, RGL2 C-158 showed
strong preferential binding to only Ras and Rap1b.
FIG. 1. RGL2 is a new member of the RalGDS family. Panel A,
nucleotide sequence and conceptual translation of a partial cDNA en-
coding RGL2. Underlined nucleotides (1–771) represent the CDC25
homology domain. The RBD is double underlined. Panel B, multiple
sequence alignment of the Ras/Rap binding domain from mouse RGL,
mouse RalGDS, and human RGL2. Alignments were created using
PILEUP.
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RGL2 C-158 Interacts with Rap1b and Ha-Ras in Vitro—To
confirm and extend the observations from the two-hybrid bind-
ing analyses, we generated a GST fusion protein containing
RGL2 C-158 for in vitro binding experiments. We measured the
relative affinity of RGL2 C-158 for recombinant Rap1b and
Ha-Ras. RGL2 C-158 exhibited approximately the same levels
of binding to Ha-Ras when compared with Rap1b at all points
tested (EC50 5 100–150 nM) (Fig. 2A). This is comparable to
affinities measured for Ras binding with the NH2-terminal Ras
binding domain of Raf-1 (38, 47).
The failure of RGL2 C-158 to bind to Rap1b S17N in two-
hybrid assays suggested that RGL2 preferentially interacted
with the GTP-bound form of Rap1b and Ras. To test this,
Ha-Ras was loaded with either GDP or GTP and binding reac-
tions performed to compare the relative affinity of RGL2 C-158
for the two conformations of Ha-Ras. The results clearly dem-
onstrated that RGL2 C-158 bound exclusively to Ras-GTP (Fig.
2B). Within the range of quantities of Ras tested (30–500 nM)
we were unable to detect any specific binding to the GDP-bound
form of the protein. This result contrasts with that of Raf-1,
which binds preferentially but not exclusively to Ras in the
GTP-bound form (38, 47).
The RGL2 RBD Is a Dominant Inhibitor of Ras in NIH 3T3
Cells—To determine if the RGL2 RBD (1–98, relative to C-158)
could interact with Ras in vivo, we utilized approaches that
have been useful in demonstrating the interaction of the Raf-1
RBD with Ras. We have shown previously that coexpression of
various Raf-1 fragments with oncogenic Ras caused inhibition
of Ras-mediated signaling and transformation (38), presum-
ably as a consequence of the ability of these fragments to form
inactive complexes with Ras. Like the Raf-1 RBD, we observed
that coexpression of the RGL2 RBD with Ras caused a signif-
icant reduction in oncogenic Ras-induced activation of tran-
scription from the ets/AP-1 Ras-responsive promoter element
and focus formation in NIH 3T3 transformation assays (80 and
50%, respectively) (Fig. 3). These observations suggest that
RGL2 may interact with Ras in vivo.
DISCUSSION
It is becoming increasingly apparent that Ras-dependent
cellular transformation is mediated by interactions with mul-
tiple effector proteins (5–13). Although Ras and Rap share
interaction with common candidate effector targets (e.g. Raf-1,
RalGDS), they exhibit divergent signaling and biological activ-
ities. Whereas constitutively activated mutants of Ras cause
cellular transformation, analogous mutants of Rap1a antago-
nize Ras signaling and transformation (23, 24, 27–34). There-
fore, identifying common and distinct effectors that interact
with these two closely related proteins may provide a critical
clue to establish the mechanism by which Rap antagonizes Ras
and to define the distinct signaling pathways controlled by Rap
proteins. In the present study, we used yeast two-hybrid li-
brary screening analysis and identified RGL2 as a candidate
effector for Ras and Rap. RGL2 constitutes the third member of
a family of proteins that are candidate GEFs for the Ral family
of Ras-related GTPases. Like Raf-1, the interaction of the Ras/
Rap binding domain of RGL2 (RGL2 C-158) with Ras and Rap
requires an intact effector domain. Also like Raf-1, RGL2
(RGL2 C-158) was able to block oncogenic Ras signaling and
transformation. However, whereas Raf-1 showed preferential
binding to the active, GTP-bound forms of Ras and Rap, RGL2
C-158 showed exclusive binding to GTP-Ras. These findings
support the possibility that RGL2 interacts with Ras in mam-
malian cells. Thus RGL2 interaction with Rap may represent a
mechanism for Rap inhibition of Ras.
Recent evidence indicates that Ras interaction with non-Raf
TABLE I


















a The yeast strain HF7c was cotransformed with C-158 and Rap1b or
other GTPases. After 3 days of growth, colonies were assayed for b-ga-
lactosidase activity. 11 indicates strong activity; 1 indicates weak, but
detectable, activity; 2 indicates no activity. The results were obtained
at least two times in independent experiments.
FIG. 2. RGL2 C-158 binding to Rap1b and Ras in vitro. The
RGL2 C-158 GST fusion protein (8 pmol) was incubated with the indi-
cated low molecular weight G protein for 60 min at 4 °C. Panel A,
binding curves comparing RGL2 C-158 binding to Rap1b (å) and Ha-
Ras (l). Panel B, binding curves comparing RGL2 C-158 binding to
Ha-Ras-GTP (l) and Ha-Ras-GDP (å). Results are the average of
triplicate samples and are representative of at least two independent
experiments giving similar results.
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effector targets contributes significantly to Ras transforming
activity. For example, analysis of two Ras effector domain
mutants that fail to bind to and activate Raf showed that these
mutants retained strong tumorigenic transforming activity
(18). In the present study, we show that one of these mutants,
Ras G12V;E37G, retained the capacity to bind to RGL2, indi-
cating that RGL2 could serve as a critical effector for mediating
the transforming action of this mutant Ras protein. Consistent
with this, we have observed that coexpression of RalGDS syn-
ergistically enhanced the transforming activity of an effector
domain mutant that had lost RalGDS binding (Ras
G12V;T35S).2
Another possible role for RGL2 might be as an effector me-
diating signaling from R-Ras and/or TC21. Like Ras, constitu-
tively activated mutants of TC21 and R-Ras cause potent tu-
morigenic transformation of NIH 3T3 cells (19–22). However,
neither TC21 nor R-Ras causes the same up-regulation of Raf-1
or B-Raf kinase activity seen with Ras transformation of
NIH 3T3 cells.3 Thus, these two Ras-related proteins utilize
Raf-independent signaling pathways to cause transformation.
We found that RGL2 C-158 also bound to TC21 and R-Ras,
although this interaction was weaker than that seen with Ras
or Rap. Similarly, it has been reported that RalGDS also inter-
acts with TC21 and R-Ras (9, 48). Thus, these candidate Ral
GEFs may represent the key effectors for mediating the trans-
forming actions of TC21 and R-Ras.
Full morphological transformation induced by Ras is depend-
ent upon the activities of the Ras-related GTPases Rac1, RhoA
and Ral (16, 17, 49). Recent data support a role for RalGDS as
a functional Ras effector (49, 50). However, the effectors cou-
pling Ras to Rac1/RhoA have not yet been identified. The
two-domain structure of the members of the RalGDS family
makes them ideal candidates for coupling Ras or Rap activity
with that of other GTPase-mediated signaling cascades. Since
the RGL2 CDC25-related domain shares the strongest se-
quence similarity with RalGDS, it is possible that RGL2 also
functions as a GEF for Ral or Ral-related proteins. Therefore,
Ras or Rap binding to RGL2 may stimulate this activity, which
in turn may result in the subsequent activation of other low
molecular weight GTPases. Future studies will be aimed at
determining whether RGL2 functions in an overlapping but
distinct manner as RalGDS or if instead it couples active Ras to
other Ral-related GTPases.
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